Drugs / GS-4774
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01779505 | Jan → Aug 2013 | — | Gilead Sciences | Completed | No outcome recorded |
| Phase 22 trials · 2 missed | ||||||
| Phase 2 | NCT02174276 | Jul 2014 → Feb 2016 | chronic hepatitis B virus infection | Gilead Sciences | Completed | Missed primary |
| Phase 2 | NCT01943799 | Sep 2013 → Sep 2014 | chronic hepatitis B virus infection | Gilead Sciences | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-05-27 | GlobeImmune | Results GlobeImmune Announces Top Line Results From GS-4774 Phase 2 Trial in Virally-Suppressed Chronic HBV Patients globeimmune.com ↗
In this study, patients treated with the highest dose of GS-4774 plus ongoing oral antiviral therapy (OAV) did not show a reduction in hepatitis B surface antigen (HBsAg) at week 24, the primary endpoint of the study, but at 48 weeks had a mean -0.17 log 10 reduction of HBsAg compared with a -0.04 log 10 reduction in the OAV alone group (p=not significant). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-05-27 | GlobeImmune | GlobeImmune Announces Top Line Results From GS-4774 Phase 2 Trial in Virally-Suppressed Chronic HBV Patients globeimmune.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS-4774 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01943799 ↗ |
| Modality | Vaccine | “GS-4774, a hepatitis B virus-specific therapeutic vaccine” PMID 25045824 ↗ Jul 2014 |
| Route | Subcutaneous | “five subcutaneous injections at weekly intervals with one monthly booster” PMID 25045824 ↗ Jul 2014 |